Katrine Bosley Net Worth

The estimated Net Worth of Katrine Bosley is at least $7.4 Million dollars as of 8 January 2019. Ms. Bosley owns over 12,000 units of Genocea Biosciences Inc stock worth over $0 and over the last 10 years she sold GNCA stock worth over $7,265,361. In addition, she makes $133,416 as Independent Director at Genocea Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Bosley GNCA stock SEC Form 4 insiders trading

Katrine has made over 22 trades of the Genocea Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 12,000 units of GNCA stock worth $303,240 on 8 January 2019.

The largest trade she's ever made was selling 20,000 units of Genocea Biosciences Inc stock on 29 January 2018 worth over $775,800. On average, Katrine trades about 7,155 units every 16 days since 2015. As of 8 January 2019 she still owns at least 1,204,966 units of Genocea Biosciences Inc stock.

You can see the complete history of Ms. Bosley stock trades at the bottom of the page.

Katrine Bosley biography

Katrine S. Bosley serves as Independent Director of the Company. Ms. Bosley served as the Chief Executive Officer of Editas Medicine Inc. ("Editas") from June 2014 through February 2019. Prior to Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from September 2013 to May 2014. She served as Chief Executive Officer of Avila Therapeutics Inc. ("Avila"), from May 2009 to March 2012, when Avila was acquired by Celgene Corporation. Before Avila, she was Vice President, Strategic Operations at Adnexus Therapeutics Inc. ("Adnexus"), a BMS Company, and was Vice President, Business Development at Adnexus before that. She joined Adnexus from Biogen Idec where she held roles in business development, commercial operations, and portfolio strategy in the United States and Europe. In addition to serving as a director of our Company, Ms. Bosley currently serves as a director of Galapagos NV and Massachusetts Eye and Ear. She also is a member of the BIO Governing Board and Chair of the Emerging Companies Section of the Board. Ms. Bosley graduated from Cornell University with a B.A. in Biology.

What is the salary of Katrine Bosley?

As the Independent Director of Genocea Biosciences Inc, the total compensation of Katrine Bosley at Genocea Biosciences Inc is $133,416. There are 7 executives at Genocea Biosciences Inc getting paid more, with William Clark having the highest compensation of $1,063,000.

How old is Katrine Bosley?

Katrine Bosley is 52, she's been the Independent Director of Genocea Biosciences Inc since 2018. There are 7 older and 10 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.

What's Katrine Bosley's mailing address?

Katrine's mailing address filed with the SEC is 11 Hurley St, Cambridge, MA 02141, USA.

Insiders trading at Genocea Biosciences Inc

Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.

What does Genocea Biosciences Inc do?

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Complete history of Ms. Bosley stock trades at Editas Medicine Inc and Genocea Biosciences Inc

Genocea Biosciences Inc executives and stock owners

Genocea Biosciences Inc executives and other stock owners filed with the SEC include:

• William Clark,
  President, Chief Executive Officer, Director
• William D. Clark M.B.A.,
  Pres, CEO & Director
• Girish Aakalu,
  Chief Business Officer
• Thomas Davis,
  Chief Medical Officer
• Jessica Flechtner,
  Chief Scientific Officer
• Dr. Thomas A. Davis,
  Chief Medical Officer
• Dr. Girish N. Aakalu Ph.D.,
  Chief Bus. Officer
• Katrine Bosley,
  Independent Director
• Kenneth Bate,
  Independent Chairman of the Board
• George Siber,
  Independent Director
• Michael Higgins,
  Independent Director
• Ronald Cooper,
  Independent Director
• Ali Behbahani,
  Independent Director
• Gisela Schwab,
  Director
• Narinderjeet Singh,
  Senior Vice President - Pharmaceutical Sciences and Manufacturing
• Diantha Duvall,
  Chief Financial Officer
• Dr. Jessica Baker Flechtner,
  Chief Scientific Officer
• Diantha Duvall,
  CFO & Sec.
• Dr. Raymond D. Stapleton Jr.,
  Exec. VP of Pharmaceutical Sciences & Manufacturing
• Jacquelyn L. Sumer,
  Chief Legal & Compliance Officer
• Kevin Bitterman,
  Director
• Jonathan Poole,
  Chief Financial Officer
• Seth V Hetherington,
  Chief Medical Officer
• Paul Giannasca,
  VP of Development
• Stephen J Hoffman,
  Director
• Howard Mayer,
  Director
• Eric S Hoffman,
  Chief Business Officer
• Venture Management Co. V, L...,
  
• John Lunger,
  Director
• Michael Alfieri,
  Principle Financial Officer
• Derek M Meisner,
  SENIOR VP AND GENERAL COUNSEL
• Pamela Carroll,
  SVP IMMUNO-ONCOLOGY
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Scott D Sandell,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Peter W. Sonsini,
  10% owner
• Joshua Makower,
  10% owner
• Carmen Chang,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• Jacquelyn L Sumer,
  CHIEF LEGAL & COMPLIANCE OFF
• Robert E Jr Farrell,
  VP of Finance & Administration
• Venture Management Co. V, L...,
  
• Capital Management, Llc Lux...,
  
• Simeon George,
  Director
• & Johnson Johnson & Johnson...,
  
• Plc Gsk,
  10% owner
• Paul Edward Walker,
  10% owner
• Jennifer Lyn Herron,
  Director
• Raymond D Jr Stapleton,
  CHIEF TECHNOLOGY OFFICER